Discovery of 7-tetrahydropyran-2-yl chromans: beta-site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitors that reduce amyloid beta-protein (A beta ) in the central nervous system.
Thomas, A.A., Hunt, K.W., Volgraf, M., Watts, R.J., Liu, X., Vigers, G., Smith, D., Sammond, D., Tang, T.P., Rhodes, S.P., Metcalf, A.T., Brown, K.D., Otten, J.N., Burkard, M., Cox, A.A., Do, M.K., Dutcher, D., Rana, S., DeLisle, R.K., Regal, K., Wright, A.D., Groneberg, R., Scearce-Levie, K., Siu, M., Purkey, H.E., Lyssikatos, J.P., Gunawardana, I.W.(2014) J Med Chem 57: 878-902
- PubMed: 24397738 
- DOI: https://doi.org/10.1021/jm401635n
- Primary Citation of Related Structures:  
4N00 - PubMed Abstract: 
In an attempt to increase selectivity vs Cathepsin D (CatD) in our BACE1 program, a series of 1,3,4,4a,10,10a-hexahydropyrano[4,3-b]chromene analogues was developed. Three different Asp-binding moieties were examined: spirocyclic acyl guanidines, aminooxazolines, and aminothiazolines in order to modulate potency, selectivity, efflux, and permeability ...